American Oriental Bioengineering Inc. (OTCMKTS:AOBI) was downgraded by equities researchers at ValuEngine from a “hold” rating to a “sell” rating in a research note issued to investors on Monday, July 17th.
Shares of American Oriental Bioengineering (OTCMKTS AOBI) remained flat at $1.11 during midday trading on Monday. American Oriental Bioengineering has a one year low of $1.02 and a one year high of $5.40. The company’s 50 day moving average is $3.63 and its 200 day moving average is $4.13. The stock’s market capitalization is $79920.00.
COPYRIGHT VIOLATION WARNING: This report was originally published by StockNewsTimes and is the property of of StockNewsTimes. If you are reading this report on another site, it was illegally copied and republished in violation of international copyright and trademark legislation. The correct version of this report can be read at https://stocknewstimes.com/2017/08/05/american-oriental-bioengineering-inc-aobi-lowered-to-sell-at-valuengine-updated-updated.html.
About American Oriental Bioengineering
American Oriental Bioengineering, Inc is an integrated pharmaceutical company. The Company is engaged in development, manufacture and commercialization of a broad range of pharmaceutical and healthcare products. The Company’s business consists of prescription pharmaceutical products, over-the-counter pharmaceutical products and nutraceutical products.
To view ValuEngine’s full report, visit ValuEngine’s official website.
Receive News & Ratings for American Oriental Bioengineering Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for American Oriental Bioengineering Inc. and related companies with MarketBeat.com's FREE daily email newsletter.
